Filing Details
- Accession Number:
- 0001104659-21-093665
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-07-19 20:49:48
- Reporting Period:
- 2021-07-15
- Accepted Time:
- 2021-07-19 20:49:48
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1442836 | Mersana Therapeutics Inc. | MRSN | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1347582 | Anna Protopapas | C/O Mersana Therapeutics, Inc. 840 Memorial Drive Cambridge MA 02139 | President & Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2021-07-15 | 100,000 | $0.00 | 324,922 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-07-16 | 20,043 | $12.47 | 304,879 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-07-19 | 21,901 | $12.02 | 282,978 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Restricted Stock Units | Disposition | 2021-07-15 | 100,000 | $0.00 | 100,000 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | M | Direct |
Footnotes
- Each restricted stock unit ("RSU") listed in Table II represented a contingent right to receive one share of the Issuer's common stock upon vesting.
- Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs listed in Table II. These sales were mandated by the Issuer's election under its equity incentive plans to require the reporting person to sell a number of shares of common stock needed to satisfy her tax withholding obligations and does not represent a discretionary trade by the reporting person
- The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $12.27 to $12.61, inclusive. The reporting person undertakes to provide to Mersana Therapeutics, Inc., any security holder of Mersana Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
- The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $11.90 to $12.23, inclusive. The reporting person undertakes to provide to Mersana Therapeutics, Inc., any security holder of Mersana Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4.
- The RSUs vested in their entirety on July 15, 2021.
Billionaire Hedge Funds
